Continuous Bioprocessing Platforms

Our  proven integrated continuous biomanufacturing platform, which we call JP3, combines intensified perfusion cell culture using single-use bioreactor (SUB) technology with fully connected downstream processing operations. We produce of drug substance using hybrid (‘semi-continuous’) or fully continuous (‘end-to-end’) modes of operation using either 500L or 1000L scale SUBs depending on the amount of drug substance needed.

Our continuous manufacturing strategy combines flexibility the high mass outputs that can be achieved through the use of traditional large scale (typically 5,000-20,000L) stainless steel facilities. We have high expressing cell lines and integrated single-use upstream and downstream processing unit operations. Our innovative control strategy in enabled by our proprietary automation.

An intensified perfusion cell culture process results in a high and consistent viable cell densities. Our process controls and process analytical technologies ensure production is held in a ‘steady state’ resulting in greater product consistency. Cell death (apoptosis) is much lower compared to a fed batch process therefore less leakage of intracellular contents, such as proteases which can degrade the protein product, occurs.

The drug substance manufacturing process is scaled up to meet product demand simply by extending the perfusion time and increasing the number of downstream cycles. We have proven that we can increase productivity compared to traditional fed batch processes significantly.

Our fully end-to-end continuous bioprocessing strategy which can deliver up to 5-6/L/day is capable of reducing COGs for a monoclonal antibody by as much as 75% for a commercial product¹. We are committed to achieving COGS below US$ 50 per gram, as it lies at the core of our mission to ensure affordable access for all.

_{1) Garcia F.A & Gefroh E., Drug Discovery Today (2023)}